Citations

Clear

139 citation(s) found for "Anderson, Kenneth C".

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
Roccaro, Aldo M. , Sacco, Antonio , Thompson, Brian , Leleu, Xavier , Azab, Feda, Runnels, Judith, Jia, Xiaoying , Ngo, Hai T., Melhem, Molly, Lin, Charles P. , Rollins, Barrett J. , Azab, Abdel Kareem , Ribatti, Doménico , Witzig, Thomas E. , Anderson, Kenneth C. , Ghobrial, Irene M. , Roccaro, Aldo M

Mayo Clinic

Blood | April 29, 2009 | Volume: 113 | Issue: 26 | Pages: 6669-6680

10.1182/blood-2009-01-198408 | PMID 19401561 Get It

Abstract Detailed genomic studies have shown that cytogenetic abnormalities contribute to multiple myeloma (MM) pathogenesis and disease progression. Nevertheless, little is known about the characteristics of MM at the epigenetic level and specifically how microRNAs regulate MM progression in the context of the bone marrow milieu. Therefore, we performed microRNA expression profiling of bone marrow derived CD138+ MM cells versus their normal cellular counterparts and validated data by qRT-PCR. We identified a MM-specific microRNA signature characterized by down-expression of microRNA-15a/-16 and overexpression of microRNA-222/-221/-382/-181a/-181b (P < .01). We investigated the functional role of microRNA-15a and -16 and showed that they regulate proliferation and growth of MM cells in vitro and in vivo by inhibiting AKT serine/threonine-protein-kinase (AKT3), ribosomal-protein-S6, MAP-kinases, and NF-κB-activator MAP3KIP3. Moreover, miRNA-15a and -16 exerted their anti-MM activity even in the context of the bone marrow milieu in vitro and in vivo. These data indicate that microRNAs play a pivotal role in the biology of MM and represent important targets for novel therapies in MM.
Targeting NF-κB in Waldenstrom macroglobulinemia
Leleu, Xavier , Eeckhoute, Jérôme , Jia, Xiaoying , Roccaro, Aldo M. , Moreau, Anne-Sophie, Sacco, Antonio , Ngo, Hai T., Runnels, Judith, Melhem, Molly, Burwick, Nicolas, Azab, Abdelkareem, Azab, Feda, Hunter, Zachary R. , Hatjiharissi, Evdoxia , Carrasco, Daniel R., Hideshima, Teru , Brown, Myles , Farag, Mena S. , Treon, Steven P. , Witzig, Thomas E. , Anderson, Kenneth C. , Ghobrial, Irene M. , Roccaro, Aldo M , Hunter, Zachary R , Brown, Myles

Mayo Clinic

Blood | March 12, 2008 | Volume: 111 | Issue: 10 | Pages: 5068-5077

10.1182/blood-2007-09-115170 | PMID 18334673 Get It

Abstract The nuclear factor-κB (NF-κB) path-way has been implicated in tumor B-cell survival, growth, and resistance to therapy. Because tumor cells overcome single-agent antitumor activity, we hypothesized that combination of agents that target differentially NF-κB pathway will induce significant cytotoxicity. Therapeutic agents that target proteasome and Akt pathways should induce significant activity in B-cell malignancies as both pathways impact NF-κB activity. We demonstrated that perifosine and bortezomib both targeted NF-κB through its recruitment to the promoter of its target gene IκB using chromatin immunoprecipitation assay. This combination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediated through a combined reduction of the PI3K/Akt and ERK signaling pathways, found to be critical for survival of WM cells. Moreover, a combination of these drugs with the CD20 monoclonal antibody rituximab further increased their cytotoxic activity. Thus, effective WM therapy may require combination regimens targeting the NF-κB pathway.
Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma
Rajkumar, S. Vincent , Richardson, Paul G. , Lacy, Martha Q. , Dispenzieri, Angela , Greipp, Philip R., Schlossman, Robert, Sidor, Carolyn, Richardson, Paul Gerard Guy , Witzig, Thomas E. , Anderson, Kenneth C. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela

Mayo Clinic

Clinical Cancer Research | October 18, 2007 | Volume: 13 | Issue: 20 | Pages: 6162-6167

10.1158/1078-0432.ccr-07-0807 | PMID 17947482 Get It

Abstract Purpose: 2-Methoxyestradiol (2ME2) is an endogenous product of estradiol metabolism with antiangiogenic and antineoplastic properties. We report on the first phase II trial of 2ME2 in multiple myeloma. Experimental Design: 2ME2 was administered orally at a dose of 1,000 mg daily. Sixty patients (31 men and 29 women) were treated. After 39 patients were accrued, the dose was increased to 800 mg twice daily for the remaining patients. Results: Thirty-one patients had relapsed or refractory multiple myeloma, and 29 had plateau phase multiple myeloma. Median age was 60 years (range, 27-84 years). Therapy was well tolerated. Common adverse events included anemia (35%), fatigue (35%), nausea (25%), diarrhea (20%), hot flushes (20%), headache (17%), muscle cramps (15%), and upper respiratory tract infection (15%). Most adverse events were mild (grade 1-2); 12% experienced grade 3-4 adverse events. Median time to progression was 3.8 months, with 5.6 months for plateau phase disease and 2.3 months for relapsed multiple myeloma. Estimated progression-free survival rates for all patients at 1, 2, and 3 years were 24%, 17%, and 11%, respectively. Three patients, all with plateau phase disease, have been on study for over 4 years without progression at 50, 60, and 63 months, respectively. Minor response was noted in 2 patients. Conclusions: Although no partial responses have been seen thus far, the minor responses and prolonged stable disease seen with 2ME2 therapy are promising. Plasma levels indicate that the dose of 2ME2 was inadequate. A new formulation with better bioavailability will be tested soon in multiple myeloma.
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
Richardson, Paul G. , Sonneveld, Pieter , Irwin, David, Stadtmauer, Edward A. , Harousseau, Jean‐Luc, Ben‐Yehuda, Dina, Goldschmidt, Hartmut , Reece, Donna , Bladé, Joan , Boccadoro, Mario , Cavenagh, Jamie, Alsina, Melissa , Rajkumar, S. Vincent , Lacy, Martha Q. , Dalton, William S. , Boral, Anthony, Esseltine, Dixie‐Lee, Schenkein, David P., Richardson, Paul Gerard Guy , Schuster, Michael K. , Facon, Thierry T.F. , Lonial, Sagar , Miguel, Jesús F. San , Jakubowiak, Andrzej , Anderson, Kenneth C. , Rajkumar, S Vincent

Mayo Clinic

Blood | August 9, 2007 | Volume: 110 | Issue: 10 | Pages: 3557-3560

10.1182/blood-2006-08-036947 | PMID 17690257 Get It

Abstract Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of relapsed multiple myeloma patients showed significantly longer time to progression, higher response rate, and improved survival with single-agent bortezomib versus high-dose dexamethasone. In this updated analysis (median follow-up: 22 months), survival was assessed in both arms, and efficacy updated for the bortezomib arm. Median survival was 29.8 months for bortezomib versus 23.7 months for dexamethasone, a 6-month benefit, despite substantial crossover from dexamethasone to bortezomib. Overall and complete response rates with bortezomib were 43% and 9%, respectively; among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response. Higher response quality (100% M-protein reduction) was associated with longer response duration; response duration was not associated with time to response. These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy. This study is registered at http://clinicaltrials.gov (Study ID NCT00048230).
American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma
Kyle, Robert A. , Yee, Gary C., Somerfield, Mark R. , Flynn, Patrick J. , Halabi, Susan , Orlowski, Robert Z. , Roodman, David, Twilde, Patricia, Jagannath, Sundar , Orlowski, Robert Z. , Anderson, Kenneth C. , Halabi, Susan

Mayo Clinic

Journal of Clinical Oncology | May 22, 2007 | Volume: 25 | Issue: 17 | Pages: 2464-2472

10.1200/jco.2007.12.1269 | PMID 17515569 Get It

Purpose To update the recommendations for the use of bisphosphonates in the prevention and treatment of bone disease in multiple myeloma. The Update Committee expanded the guideline to include a discussion of osteonecrosis of the jaw (ONJ). Methods For the 2007 update, an Update Committee composed of members from the full panel completed a review and analysis of data published since 2002. Searches of Medline and the Cochrane Collaboration Library databases were performed. Recommendations For multiple myeloma patients who have, on plain radiograph(s) or imaging studies, lytic destruction of bone or spine compression fracture from osteopenia, intravenous pamidronate 90 mg delivered over at least 2 hours or zoledronic acid 4 mg delivered over at least 15 minutes every 3 to 4 weeks is recommended. Clodronate is an alternative bisphosphonate approved worldwide, except in the United States, for oral or intravenous administration. New dosing guidelines for patients with pre-existing renal impairment were added to the zoledronic acid package insert. Although no similar dosing guidelines are available for pamidronate, the Update Committee recommends that clinicians consider reducing the initial pamidronate dose in patients with pre-existing renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting. The Update Committee suggests that bisphosphonate treatment continue for a period of 2 years. At 2 years, physicians should seriously consider discontinuing bisphosphonates in patients with responsive or stable disease, but further use is at the discretion of the treating physician. The Update Committee also discusses measures regarding ONJ.
Proteomic Analysis of Waldenstrom Macroglobulinemia
Hatjiharissi, Evdoxia , Ngo, Hai T., Leontovich, Alexey A. , Leleu, Xavier , Timm, Michael, Melhem, Mona F., George, Diane, Lu, Ganwei, Alsayed, Yazan, Zeismer, Steven C., Cabanela, Miguel E., Nehme, Alex, Jia, Xiaoying , Moreau, Anne Sophie, Fonseca, Rafaël , Ghobrial, Joanna M. , Moreau, Anne Sophie, Treon, Steven P. , Gertz, Morie A. , Anderson, Kenneth C. , Witzig, Thomas E. , Ghobrial, Irene M. , Fonseca, Rafael

Mayo Clinic

Cancer Research | April 17, 2007 | Volume: 67 | Issue: 8 | Pages: 3777-3784

10.1158/0008-5472.can-06-3089 | PMID 17440091 Get It

Abstract To better understand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based protein microarrays to compare patterns of protein expression between untreated WM and normal bone marrow controls. Protein expression was defined as a &gt;2-fold or 1.3-fold change in at least 67% of the tumor samples. Proteins up-regulated by &gt;2-fold included Ras family proteins, such as Rab-4 and p62DOK, and Rho family proteins, such as CDC42GAP and ROKα. Other proteins up-regulated by &gt;1.3-fold included cyclin-dependent kinases, apoptosis regulators, and histone deacetylases (HDAC). We then compared the samples of patients with symptomatic and asymptomatic WM and showed similar protein expression signatures, indicating that the dysregulation of signaling pathways occurs early in the disease course. Three proteins were different by &gt;2-fold in symptomatic versus asymptomatic, including the heat shock protein HSP90. Elevated protein expression was confirmed by immunohistochemistry and immunoblotting. Functional significance was validated by the induction of apoptosis and inhibition of proliferation using specific HDAC and HSP90 inhibitors. This study, therefore, identifies, for the first time, multiple novel proteins that are dysregulated in WM, which both enhance our understanding of disease pathogenesis and represent targets of novel therapeutics. [Cancer Res 2007;67(8):3777–8]
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström macroglobulinemia
Moreau, Anne-Sophie, Jia, Xiaoying , Ngo, Hai T., Leleu, Xavier , O’Sullivan, Garrett, Alsayed, Yazan, Leontovich, Alexey A. , Podar, Klaus , Kutok, Jeffrey L., Daley, John, Lazo-Kallanian, Suzan, Hatjiharissi, Evdoxia , Xu, Lian, Hideshima, Teru , Raab, Marc S. , Treon, Steven P. , Anderson, Kenneth C. , Ghobrial, Irene M.

Mayo Clinic

Blood | February 7, 2007 | Volume: 109 | Issue: 11 | Pages: 4964-4972

10.1182/blood-2006-10-054577 | PMID 17284528 Get It

AbstractWaldenström macroglobulinemia (WM) is an incurable lymphoplasmacytic lymphoma with limited options of therapy. Protein kinase Cβ (PKCβ) regulates cell survival and growth in many B-cell malignancies. In this study, we demonstrate up-regulation of PKCβ protein in WM using protein array techniques and immunohistochemistry. Enzastaurin, a PKCβ inhibitor, blocked PKCβ activity and induced a significant decrease of proliferation at 48 hours in WM cell lines (IC50, 2.5-10 μM). Similar effects were demonstrated in primary CD19+ WM cells, without cytotoxicity on peripheral blood mononuclear cells. In addition, enzastaurin overcame tumor cell growth induced by coculture of WM cells with bone marrow stromal cells. Enzastaurin induced dose-dependent apoptosis at 48 hours mediated via induction of caspase-3, caspase-8, caspase-9, and PARP cleavage. Enzastaurin inhibited Akt phosphorylation and Akt kinase activity, as well as downstream p-MARCKS and ribosomal p-S6. Furthermore, enzastaurin demonstrated additive cytotoxicity in combination with bortezomib, and synergistic cytotoxicity in combination with fludarabine. Finally, in an in vivo xenograft model of human WM, significant inhibition of tumor growth was observed in the enzastaurin-treated mice (P = .028). Our studies therefore show that enzastaurin has significant antitumor activity in WM both in vitro and in vivo, providing the framework for clinical trials to improve patient outcome in WM.
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
Mulligan, George , Mitsiades, Constantine S. , Bryant, Barbara M. , Roels, Steven , Koenig, Erik , Fergus, Andrew, Huang, Yongsheng , Richardson, Paul G. , Trepicchio, William L. , Broyl, Annemiek, Sonneveld, Pieter , Shaughnessy, John D. , Bergsagel, P. Leif , Schenkein, David P., Esseltine, Dixie‐Lee, Boral, Anthony, Zhan, Fenghuang , Zhan, Fenghuang , Chng, Wee Joo , Richardson, Paul Gerard Guy , Anderson, Kenneth C. , Bergsagel, P. Leif , Zhan, Fenghuang , Mulligan, George

Mayo Clinic

Blood | December 21, 2006 | Volume: 109 | Issue: 8 | Pages: 3177-3188

10.1182/blood-2006-09-044974 | PMID 17185464 Get It

Abstract The aims of this study were to assess the feasibility of prospective pharmacogenomics research in multicenter international clinical trials of bortezomib in multiple myeloma and to develop predictive classifiers of response and survival with bortezomib. Patients with relapsed myeloma enrolled in phase 2 and phase 3 clinical trials of bortezomib and consented to genomic analyses of pretreatment tumor samples. Bone marrow aspirates were subject to a negative-selection procedure to enrich for tumor cells, and these samples were used for gene expression profiling using DNA microarrays. Data quality and correlations with trial outcomes were assessed by multiple groups. Gene expression in this dataset was consistent with data published from a single-center study of newly diagnosed multiple myeloma. Response and survival classifiers were developed and shown to be significantly associated with outcome via testing on independent data. The survival classifier improved on the risk stratification provided by the International Staging System. Predictive models and biologic correlates of response show some specificity for bortezomib rather than dexamethasone. Informative gene expression data and genomic classifiers that predict clinical outcome can be derived from prospective clinical trials of new anticancer agents.
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
Podar, Klaus , Tonon, Giovanni , Sattler, Martin , Gouill, Steven Le , Yasui, Hiroshi , Ishitsuka, Kenji , Kumar, Shaji , Pandite, Lini , Hideshima, Teru , Chauhan, Dharminder , Tai, Yu‐Tzu , Kumar, Rakesh , Anderson, Kenneth C.

Mayo Clinic

Proceedings of the National Academy of Sciences | December 12, 2006 | Volume: 103 | Issue: 51 | Pages: 19478-19483

10.1073/pnas.0609329103 | PMID 17164332 Get It

A critical role for vascular endothelial factor (VEGF) has been demonstrated in multiple myeloma (MM) pathogenesis. Here, we characterized the effect of the small-molecule VEGF receptor inhibitor pazopanib on MM cells in the bone marrow milieu. Pazopanib inhibits VEGF-triggered signaling pathways in both tumor and endothelial cells, thereby blocking in vitro MM cell growth, survival, and migration, and inhibits VEGF-induced up-regulation of adhesion molecules on both endothelial and tumor cells, thereby abrogating endothelial cell-MM cell binding and associated cell proliferation. We show that pazopanib is the first-in-class VEGF receptor inhibitor to inhibit in vivo tumor cell growth associated with increased MM cell apoptosis, decreased angiogenesis, and prolonged survival in a mouse xenograft model of human MM. Low-dose pazopanib demonstrates synergistic cytotoxicity with conventional (melphalan) and novel (bortezomib and immunomodulatory drugs) therapies. Finally, gene expression and signaling network analysis show transcriptional changes of several cancer-related genes, in particular c-Myc. Using siRNA, we confirm the role of c-Myc in VEGF production and secretion, as well as angiogenesis. These preclinical studies provide the rationale for clinical evaluation of pazopanib, alone and in combination with conventional and novel therapies, to increase efficacy, overcome drug resistance, reduce toxicity, and improve patient outcome in MM.
Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma
Francis, Lanie, Alsayed, Yazan, Leleu, Xavier , Jia, Xiaoying , Singha, Ujjal K. , Anderson, Judith L., Timm, Michael, Ngo, Hai T., Lu, Ganwei, Huston, Alissa , Ehrlich, Lori A. , Dimmock, Elizabeth, Lentzsch, Suzanne , Hideshima, Teru , Roodman, G. David, Anderson, Kenneth C. , Ghobrial, Irene M.

Mayo Clinic

Clinical Cancer Research | November 22, 2006 | Volume: 12 | Issue: 22 | Pages: 6826-6835

10.1158/1078-0432.ccr-06-1331 | PMID 17121904 Get It

Abstract Purpose: The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (mTOR) pathway and the heat shock protein family are up-regulated in multiple myeloma and are both regulators of the cyclin D/retinoblastoma pathway, a critical pathway in multiple myeloma. Inhibitors of mTOR and HSP90 protein have showed in vitro and in vivo single-agent activity in multiple myeloma. Our objective was to determine the effects of the mTOR inhibitor rapamycin and the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on multiple myeloma cells. Experimental Design: Multiple myeloma cell lines were incubated with rapamycin (0.1-100 nmol/L) and 17-AAG (100-600 nmol/L) alone and in combination. Results: In this study, we showed that the combination of rapamycin and 17-AAG synergistically inhibited proliferation, induced apoptosis and cell cycle arrest, induced cleavage of poly(ADP-ribose) polymerase and caspase-8/caspase-9, and dysregulated signaling in the phosphatidylinositol 3-kinase/AKT/mTOR and cyclin D1/retinoblastoma pathways. In addition, we showed that both 17-AAG and rapamycin inhibited angiogenesis and osteoclast formation, indicating that these agents target not only multiple myeloma cells but also the bone marrow microenvironment. Conclusions: These studies provide the basis for potential clinical evaluation of this combination for multiple myeloma patients.